BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lymphoma AND MYB, c-myb_CDS, 4602, ENSG00000118513, P10242, efg, Cmyb, c-myb
178 results:

  • 1. Circular ZDHHC11 supports Burkitt lymphoma growth independent of its miR-150 binding capacity.
    Liu Y; Zhao X; Seitz A; Hooijsma AA; Ravanbakhsh R; Sheveleva S; de Jong D; Koerts J; Dzikiewicz-Krawczyk A; van den Berg A; Ziel-Swier LJYM; Kluiver J
    Sci Rep; 2024 Apr; 14(1):8730. PubMed ID: 38627588
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Latent Epstein-Barr virus infection collaborates with Myc over-expression in normal human B cells to induce Burkitt-like lymphomas in mice.
    Bristol JA; Nelson SE; Ohashi M; Casco A; Hayes M; Ranheim EA; Pawelski AS; Singh DR; Hodson DJ; Johannsen EC; Kenney SC
    PLoS Pathog; 2024 Apr; 20(4):e1012132. PubMed ID: 38620028
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Integrated analysis of transcriptome and genome variations in pediatric T cell acute lymphoblastic leukemia: data from north Indian tertiary care center.
    Singh M; Sharma P; Bhatia P; Trehan A; Thakur R; Sreedharanunni S
    BMC Cancer; 2024 Mar; 24(1):325. PubMed ID: 38459434
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Transcriptome Analysis in Mexican Adults with Acute Lymphoblastic Leukemia.
    Cruz-Miranda GM; Olarte-Carrillo I; Bárcenas-López DA; Martínez-Tovar A; Ramírez-Bello J; Ramos-Peñafiel CO; García-Laguna AI; Cerón-Maldonado R; May-Hau D; Jiménez-Morales S
    Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339034
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Suppression of super-enhancer-driven TAL1 expression by KLF4 in T-cell acute lymphoblastic leukemia.
    Noura M; Matsuo H; Yasuda T; Tsuzuki S; Kiyoi H; Hayakawa F
    Oncogene; 2024 Feb; 43(6):447-456. PubMed ID: 38102337
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. S1P-S1PR3-RAS promotes the progression of S1PR3
    Zhu D; Jiang T; Ma D; Zhang H; Zhang J; Lv W; Gong M; Wang H; Liu Z; Su H; Zeng L; Liu S; Tang S; Yang B; Tshavuka FI; Fu G; Liu Z; Peng D; Liu H; Yan Z; Cao Z; Zhao H; He TC; Yu J; Shu Y; Zou L
    Leukemia; 2023 Oct; 37(10):1982-1993. PubMed ID: 37591940
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Increased myb alternative promoter usage is associated with relapse in acute lymphoblastic leukemia.
    Fehr A; Arvidsson G; Nordlund J; Lönnerholm G; Stenman G; Andersson MK
    Genes Chromosomes Cancer; 2023 Oct; 62(10):597-606. PubMed ID: 37218648
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. A phase I study of the combination of palbociclib and dexamethasone for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia.
    Wilde L; Porazzi P; Trotta R; De Dominici M; Palmisiano N; Keiffer G; Rancani K; Yingling K; Calabretta B; Kasner M
    Leuk Res; 2023 Jun; 129():107075. PubMed ID: 37079999
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Harnessing the myb-dependent TAL1 5'super-enhancer for targeted therapy in T-ALL.
    Smith C; Touzart A; Simonin M; Tran-Quang C; Hypolite G; Latiri M; Andrieu GP; Balducci E; Dourthe MÉ; Goyal A; Huguet F; Petit A; Ifrah N; Baruchel A; Dombret H; Macintyre E; Plass C; Ghysdael J; Boissel N; Asnafi V
    Mol Cancer; 2023 Jan; 22(1):12. PubMed ID: 36650499
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. TAL1 activation in T-cell acute lymphoblastic leukemia: a novel oncogenic 3' neo-enhancer.
    Smith C; Goyal A; Weichenhan D; Allemand E; Mayakonda A; Toprak U; Riedel A; Balducci E; Manojkumar M; Pejkovska A; Mücke O; Sollier E; Bakr A; Breuer K; Lutsik P; Hermine O; Spicuglia S; Asnafi V; Plass C; Touzart A
    Haematologica; 2023 May; 108(5):1259-1271. PubMed ID: 36632736
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. A comprehensive landscape of transcription profiles and data resources for human leukemia.
    Luo M; Miao YR; Ke YJ; Guo AY; Zhang Q
    Blood Adv; 2023 Jul; 7(14):3435-3449. PubMed ID: 36595475
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. MiR-150 in HTLV-1 infection and T-cell transformation.
    D'Agostino DM; Raimondi V; Silic-Benussi M; Ciminale V
    Front Immunol; 2022; 13():974088. PubMed ID: 36072598
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Prognostic utility of key copy number alterations in T cell acute lymphoblastic leukemia.
    Kumari S; Ali MS; Singh J; Arora M; Verma D; Pandey AK; Benjamin M; Bakhshi S; Palanichamy JK; Sharma A; Singh I; Tanwar P; Singh AR; Pushpam D; Qamar I; Chopra A
    Hematol Oncol; 2022 Oct; 40(4):577-587. PubMed ID: 35644022
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. The Role of the MYC/miR-150/myb/ZDHHC11 Network in Hodgkin lymphoma and Diffuse Large B-Cell lymphoma.
    Ziel-Swier LJYM; Liu Y; Seitz A; de Jong D; Koerts J; Rutgers B; Veenstra R; Razak FRA; Dzikiewicz-Krawczyk A; van den Berg A; Kluiver J
    Genes (Basel); 2022 Jan; 13(2):. PubMed ID: 35205272
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.
    Mill CP; Fiskus W; DiNardo CD; Birdwell C; Davis JA; Kadia TM; Takahashi K; Short N; Daver N; Ohanian M; Borthakur G; Kornblau SM; Green MR; Qi Y; Su X; Khoury JD; Bhalla KN
    Blood; 2022 Feb; 139(6):907-921. PubMed ID: 34601571
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Identification of mutations that cooperate with defects in B cell transcription factors to initiate leukemia.
    Heltemes-Harris LM; Hubbard GK; LaRue RS; Munro SA; Yang R; Henzler CM; Starr TK; Sarver AL; Kornblau SM; Farrar MA
    Oncogene; 2021 Oct; 40(43):6166-6179. PubMed ID: 34535769
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Infant T-cell acute lymphoblastic leukaemia with t(6;7) (TCRB-myb) translocation.
    Ramdeny PS; Mullanfroze K; de Lorenzo P; Grazia Valsecchi M; Meijerink J; Pieters R; Baruchel A; Vora A
    Br J Haematol; 2021 Aug; 194(3):613-616. PubMed ID: 34212378
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia.
    Tavakoli Shirazi P; Eadie LN; Page EC; Heatley SL; Bruning JB; White DL
    Cancer Lett; 2021 Aug; 512():28-37. PubMed ID: 33971281
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Inhibiting the "Undruggable" RAS/Farnesyltransferase (FTase) Cancer Target by Manumycin-related Natural Products.
    Silva LR; da Silva-Júnior EF
    Curr Med Chem; 2022; 29(2):189-211. PubMed ID: 33719954
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. myb rearrangements and over-expression in T-cell acute lymphoblastic leukemia.
    Bardelli V; Arniani S; Pierini V; Pierini T; Di Giacomo D; Gorello P; Moretti M; Pellanera F; Elia L; Vitale A; Storlazzi CT; Tolomeo D; Mastrodicasa E; Caniglia M; Chiaretti S; Ruggeri L; Roti G; Schwab C; Harrison CJ; Almeida A; Pieters T; Van Vlierberghe P; Mecucci C; La Starza R
    Genes Chromosomes Cancer; 2021 Jul; 60(7):482-488. PubMed ID: 33611795
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 9.